Allogene upgraded at Citizens after Q4 update
Citizens upgraded Allogene Therapeutics (NASDAQ:ALLO) to Market Perform from Market Underperform on Friday, establishing a $5 ...
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript March 13, 2025 Seres Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.1, ...
Allogene's Q4 Loss Narrower Than Expected, Revenues Nil
ALLO's fourth-quarter earnings beat estimates. Devoid of marketed products, the company records no sales in the quarter.
RBC Capital Sticks to Their Buy Rating for Allogene Therapeutics (ALLO)
In a report released yesterday, Luca Issi from RBC Capital maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report), with a ...
Piper Sandler Sticks to Their Buy Rating for Allogene Therapeutics (ALLO)
Piper Sandler analyst Biren Amin maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report) today and set a price target of ...
The Manila Times18h
Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update
FDA Clearance for the RESOLUTION Basket Trial in Rheumatology Trial Initiation Targeted for Mid-2025; Proof-of-Concept Data ...
Allogene Therapeutics: Q4 Earnings Snapshot
Allogene Therapeutics Inc. (ALLO) on Thursday reported a loss of $59.9 million in its fourth quarter. On a per-share basis, the South San Francisco, California-based company said it had a loss of 28 ...
Seres Therapeutics, Inc.: Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Recent FDA feedback received on SER-155 allogeneic hematopoietic stem cell transplant (allo-HSCT) next study provides support for the proposed primary efficacy endpoint of reduction in bloodstream inf ...